181 related articles for article (PubMed ID: 37377898)
21. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
Hirth M; Gandla J; Höper C; Gaida MM; Agarwal N; Simonetti M; Demir A; Xie Y; Weiss C; Michalski CW; Hackert T; Ebert MP; Kuner R
Gastroenterology; 2020 Aug; 159(2):665-681.e13. PubMed ID: 32330476
[TBL] [Abstract][Full Text] [Related]
22. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
Baratelli F; Takedatsu H; Hazra S; Peebles K; Luo J; Kurimoto PS; Zeng G; Batra RK; Sharma S; Dubinett SM; Lee JM
J Transl Med; 2008 Jul; 6():38. PubMed ID: 18644162
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
24. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
[TBL] [Abstract][Full Text] [Related]
25. The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma.
Avram G; Sánchez-Sendra B; Martín JM; Terrádez L; Ramos D; Monteagudo C
Histopathology; 2013 Dec; 63(6):852-61. PubMed ID: 24102908
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas.
Zhao DX; Li ZJ; Zhang Y; Zhang XN; Zhao KC; Li YG; Zhang MM; Yu XW; Liu MY; Li Y
Cell Immunol; 2014; 289(1-2):155-61. PubMed ID: 24838092
[TBL] [Abstract][Full Text] [Related]
27. Chemokine (C‑C motif) ligand 21/C‑C chemokine receptor type 7 triggers migration and invasion of human lung cancer cells by epithelial‑mesenchymal transition via the extracellular signal‑regulated kinase signaling pathway.
Zhong G; Chen L; Yin R; Qu Y; Bao Y; Xiao Q; Zhang Z; Shen Y; Li C; Xu Y; Zou Z; Tian H
Mol Med Rep; 2017 Jun; 15(6):4100-4108. PubMed ID: 28487957
[TBL] [Abstract][Full Text] [Related]
28. Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients.
Rossi E; Cellini F; Pagliara MM; Sammarco MG; Pedone RR; Lancellotta V; Tagliaferri L; Quirino M; Gambacorta MA; Blasi MA; Tortora G; Schinzari G
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672442
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
[TBL] [Abstract][Full Text] [Related]
30. Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes.
Caidahl K; Hartford M; Ravn-Fischer A; Lorentzen E; Yndestad A; Karlsson T; Aukrust P; Ueland T
J Am Coll Cardiol; 2019 Aug; 74(6):774-782. PubMed ID: 31395128
[TBL] [Abstract][Full Text] [Related]
31. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Jamal R; Lapointe R; Cocolakis E; Thébault P; Kazemi S; Friedmann JE; Dionne J; Cailhier JF; Bélanger K; Ayoub JP; Le H; Lambert C; El-Hajjar J; van Kempen LC; Spatz A; Miller WH
J Immunother Cancer; 2017 Nov; 5(1):83. PubMed ID: 29157311
[TBL] [Abstract][Full Text] [Related]
32. Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.
Poelaert BJ; Romanova S; Knoche SM; Olson MT; Sliker BH; Smits K; Dickey BL; Moffitt-Holida AEJ; Goetz BT; Khan N; Smith L; Band H; Mohs AM; Coulter DW; Bronich TK; Solheim JC
J Control Release; 2020 Nov; 327():266-283. PubMed ID: 32711026
[TBL] [Abstract][Full Text] [Related]
33. Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation.
Fevang B; Yndestad A; Damås JK; Halvorsen B; Holm AM; Beiske K; Aukrust P; Frøland SS
Clin Exp Immunol; 2009 Nov; 158(2):237-45. PubMed ID: 19747210
[TBL] [Abstract][Full Text] [Related]
34. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis.
Luther SA; Bidgol A; Hargreaves DC; Schmidt A; Xu Y; Paniyadi J; Matloubian M; Cyster JG
J Immunol; 2002 Jul; 169(1):424-33. PubMed ID: 12077273
[TBL] [Abstract][Full Text] [Related]
35. Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
Padonou F; Vanhulst T; Langouo-Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):63-68. PubMed ID: 38441065
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of the chemokine CCL21 in human colorectal adenocarcinomas.
Mumtaz M; Wågsäter D; Löfgren S; Hugander A; Zar N; Dimberg J
Oncol Rep; 2009 Jan; 21(1):153-8. PubMed ID: 19082456
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.
Sah VR; Karlsson J; Jespersen H; Lindberg MF; Nilsson LM; Ny L; Nilsson JA
Melanoma Res; 2022 Aug; 32(4):241-248. PubMed ID: 34753889
[TBL] [Abstract][Full Text] [Related]
39. High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19.
Tveita A; Murphy SL; Holter JC; Kildal AB; Michelsen AE; Lerum TV; Kaarbø M; Heggelund L; Holten AR; Finbråten AK; Müller KE; Mathiessen A; Bøe S; Fevang B; Granerud BK; Tonby K; Lind A; Dudman SG; Henriksen KN; Müller F; Skjønsberg OH; Trøseid M; Barratt-Due A; Dyrhol-Riise AM; Aukrust P; Halvorsen B; Dahl TB; Ueland T;
J Infect Dis; 2022 Dec; 226(12):2150-2160. PubMed ID: 35876699
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
